|
Report Date : |
23.07.2012 |
IDENTIFICATION DETAILS
|
Name : |
VITAL HEALTH CARE PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
19.01.1998 |
|
|
|
|
Com. Reg. No.: |
11-113058 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 38.020 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24230MH1998PTC113058 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMV06794E |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturers and Suppliers of Pharmaceuticals, Bulk Drugs, Medicines
etc. |
|
|
|
|
No. of Employees
: |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (49) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 830000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually Correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established company having satisfactory track. Trade
relations are reported as fair. Business is active. Payments are reported to
be usually correct and as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
|
Agency Name |
Rating |
|
CRISIL |
BB/Positive |
Rating Explanations
|
AAA (Highest Safety) |
Instruments with this rating
are considered to have the highest degree of safety regarding timely
servicing of financial obligations. Such instruments carry lowest credit
risk. |
|
AA (High Safety) |
Instruments with this
rating are considered to have high degree of safety regarding timely
servicing of financial obligations. Such instruments carry very low credit
risk. |
|
A (Adequate Safety) |
Instruments with this
rating are considered to have adequate degree of safety regarding timely servicing
of financial obligations. Such instruments carry low credit risk. |
|
BBB (Moderate Safety) |
Instruments with this
rating are considered to have moderate degree of safety regarding timely
servicing of financial obligations. Such instruments carry moderate credit
risk. |
|
BB (Moderate Risk) |
Instruments with this
rating are considered to have moderate risk of default regarding timely
servicing of financial obligations. |
|
B (High Risk) |
Instruments with this rating
are considered to have high risk of default regarding timely servicing of
financial obligations. |
|
C (Very High Risk) |
Instruments with this
rating are considered to have very high risk of default regarding timely
servicing of financial obligations. |
|
D (Default) |
Instruments with this
rating are in default or are expected to be in default soon. |
RBI DEFAILTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
Subject’s name has been found enlisted as a
defaulter in the publicly available RBI Defaulters’ list and the details of the
same are as under :
|
Borrowers’ Name : |
|
|
Address : |
|
|
Name of Individual : |
|
|
Name of Credit Grantors / Bank & Branch: |
|
|
Amount (Rs. In Millions) : |
|
LOCATIONS
|
Registered / Corporate Office : |
Venkatesh Mahant Road, Extension, Uttkarsh Mandal Circle, Vile Parle
(East), Mumbai – 400057, Maharashtra, India |
|
Tel. No.: |
91-22-26183641/26145652/26136946 |
|
Fax No.: |
91-22-26136945 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory 1 / Administrative Office : |
Plot No.1416-19 and 1420, 1507/1 and 1507/2, 1601/1 and 1601/2,
G.I.D.C. Estate, Phase III, Vapi – 396195, Gujarat, India |
|
|
|
|
Factory 2 : |
Plot No. 1710 and A1/2208 G.I.D.C Estate, Phase III, Vapi – 396195,
Gujarat, India |
|
E-Mail : |
DIRECTORS
AS ON 31.03.2011
|
Name : |
Mr. Laltaprasad Shrinath Maurya |
|
Designation : |
Director |
|
Address : |
Ashok Nagar, Chanod Colony, Vapi – 396195, Gujarat, India |
|
Date of Birth/Age : |
26.07.1955 |
|
Date of Appointment : |
15.05.2005 |
|
DIN No.: |
00202949 |
Other Directorship:
|
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
U24230MH1998PTC113058 |
Vital
Health Care Private Limited |
Director |
15/05/2005 |
15/05/2005 |
Active |
NO |
|
U24230MH2003PTC143328 |
Vital
Lifesciences Private Limited |
Director |
31/03/2006 |
31/03/2006 |
Active |
NO |
|
U24230MH2002PTC136195 |
Vital
Laboratories Private Limited |
Director |
24/04/2009 |
24/04/2009 |
Active |
NO |
|
Name : |
Mr. Shri Gopal Rangnath Bajaj |
|
Designation : |
Director |
|
Address : |
Venkatesh, Mahant Road Extension, Uttkarsh Mandal Circle, Vile Parle
(East), Mumbai – 400057, Maharashtra, India |
|
Date of Birth/Age : |
04.01.1943 |
|
Date of Appointment : |
31.03.2001 |
|
DIN No.: |
00983198 |
Other Directorship:
|
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
U24200MH1981PTC023725 |
Padma
Pharmaceuticals Private Limited |
Director |
21/01/1981 |
21/01/1981 |
Active |
NO |
|
U24230MH1998PTC113058 |
Vital
Health Care Private Limited |
Director |
31/03/2001 |
31/03/2001 |
Active |
NO |
|
U24230MH2002PTC136195 |
Vital
Laboratories Private Limited |
Managing
director |
13/06/2002 |
13/06/2002 |
Active |
NO |
|
U24230MH2003PTC143328 |
Vital
Lifesciences Private Limited |
Director |
1/09/2005 |
1/09/2005 |
Active |
NO |
|
U51109WB2008PTC126102 |
Nabaratna
Vinimay Private Limited |
Director |
9/04/2010 |
9/04/2010 |
Active |
NO |
|
Name : |
Mr. Rajiv Shri Gopal Bajaj |
|
Designation : |
Director |
|
Address : |
Venkatesh, 2nd Floor, Mahant Road Extension, Uttkarsh
Mandal Circle, Vile Parle (East), Mumbai – 400057, Maharashtra, India |
|
Date of Birth/Age : |
10.01.1965 |
|
Date of Appointment : |
31.03.2001 |
|
DIN No.: |
01659971 |
Other Directorship:
|
CIN |
Name
of the Company |
Current
designation of the director |
Date
of appointment at current designation |
Original
date of appointment |
Company
Status |
Defaulting
status |
|
U24200MH1981PTC023725 |
Padma
Pharmaceuticals Private Limited |
Director |
22/12/1983 |
22/12/1983 |
Active |
NO |
|
U24230MH1998PTC113058 |
Vital
Health Care Private Limited |
Director |
31/03/2001 |
31/03/2001 |
Active |
NO |
|
U24230MH2002PTC136195 |
Vital
Laboratories Private Limited |
Director |
13/06/2002 |
13/06/2002 |
Active |
NO |
|
U24230MH2003PTC143328 |
Vital
Lifesciences Private Limited |
Director |
1/09/2005 |
1/09/2005 |
Active |
NO |
|
U51109WB2008PTC126102 |
Nabaratna
Vinimay Private Limited |
Director |
9/04/2010 |
9/04/2010 |
Active |
NO |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 31.03.2011
|
Names of Shareholders |
No. of Shares |
|
Dipika R Bajaj |
434420 |
|
G.D.Bajaj |
618250 |
|
Rajiv S Bajaj |
374500 |
|
Rajiv S. Bajaj (HUF) |
326000 |
|
S. R. Bajaj |
479080 |
|
S. R. Bajaj (HUF) |
557500 |
|
Padma Pharmaceuticals Private Limited, India |
1010500 |
|
L.P. Maurya |
1750 |
|
TOTAL |
3802000 |
Equity Share Break up (Percentage of Total Equity)
AS ON 15.06.2011
|
Category |
Percentage |
|
Bodies corporate |
26.58 |
|
Directors or relatives of Directors |
73.42 |
|
TOTAL |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturers and Suppliers of Pharmaceuticals, Bulk Drugs, Medicines
etc |
||||||||
|
|
|
||||||||
|
Products : |
|
PRODUCTION STATUS AS ON 31.03.2011
|
Particulars |
Unit |
Installed
Capacity |
Actual
Production |
|
Quinine Salts and Derivatives |
Kgs. |
120000 |
52645.95 |
|
Artimisinine and Derivatives |
Kgs. |
24000 |
11255.33 |
|
Nimesuilide and Derivatives |
Kgs. |
180000 |
104456 |
|
Cinchonine and Derivatives |
Kgs. |
12000 |
468 |
|
Lumefantrine and Derivatives |
Kgs. |
40000 |
18578.64 |
Note : As certified by the Director and accepted by the
Auditors. Licensed Capacity per annum is not indicated due to the abolition of
industrial licenses as per notification no; 477 (E) dated July 1991 issued
under The Industries (Development and Regulation) Act, 1951.
GENERAL INFORMATION
|
No. of Employees : |
Not Available |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Bankers : |
State Bank of India, Industrial Finance Branch, Sakinaka, 1st
Floor, Saki Vihar Road, Sakinaka, Andheri (East), Mumbai-400072, Maharashtra,
India |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Shantilal Chandaliya and Company Chartered Accountants |
|
Address : |
G-6/7, Amit Industrial Premises, 61, Dr. S.S Rao Road, Parel, Mumbai –
400012, Maharashtra, India |
|
Tel. No.: |
91-22-40690701 |
|
Fax No.: |
91-22-40690711 |
|
E-Mail : |
|
|
PAN.: |
AAPCS5584D |
CAPITAL STRUCTURE
AS ON 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
4500000 |
Equity Shares |
Rs.10/- each |
Rs.45.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
3802000 |
Equity Shares |
Rs.10/- each |
Rs.38.020
Millions |
|
|
|
|
|
NOTE
Of the above 300000 shares have been allotted
as fully paid up on amalgamation of B. M. Pigments Private Limited with the
company 1.260 millions shares have been allotted as fully paid up on account of
Bonus by Capitalization of General Reserve.
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
38.020 |
38.020 |
32.810 |
|
|
2] Share Application Money |
0.000 |
0.000 |
52.100 |
|
|
3] Reserves & Surplus |
171.208 |
149.405 |
88.609 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
209.228 |
187.425 |
173.519 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
302.006 |
192.422 |
41.095 |
|
|
2] Unsecured Loans |
18.641 |
38.265 |
46.936 |
|
|
TOTAL BORROWING |
320.647 |
230.687 |
88.031 |
|
|
DEFERRED TAX LIABILITIES |
15.757 |
15.392 |
10.643 |
|
|
|
|
|
|
|
|
TOTAL |
545.632 |
433.504 |
272.193 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
217.967 |
214.753 |
198.283 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.005 |
0.005 |
0.005 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
264.322
|
159.584
|
287.642 |
|
|
Sundry Debtors |
146.284
|
189.322
|
102.365 |
|
|
Cash & Bank Balances |
20.021
|
15.445
|
9.218 |
|
|
Other Current Assets |
0.000
|
0.000
|
0.000 |
|
|
Loans, Advances and Deposits |
37.982
|
25.586
|
32.657 |
|
Total
Current Assets |
468.609
|
389.937
|
431.882 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors and Other Current Liabilities |
140.559
|
170.801
|
357.977 |
|
|
Provisions |
0.390
|
0.390
|
0.000 |
|
Total
Current Liabilities |
140.949
|
171.191
|
357.977 |
|
|
Net Current Assets |
327.660
|
218.746
|
73.905 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
545.632 |
433.504 |
272.193 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
INCOME FOR THE
YEAR |
751.939 |
661.518 |
559.550 |
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
32.447 |
15.104 |
6.761 |
|
|
|
|
|
|
|
Less |
TAX |
10.644 |
1.198 |
3.048 |
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
21.803 |
13.906 |
3.713 |
|
|
|
|
|
|
|
|
EARNINGS
PER SHARE |
5.73 |
4.24 |
1.13 |
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
Return on Total Assets (PBT/Total Assets} |
(%) |
4.73
|
2.50
|
1.07 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.15
|
0.08
|
0.04 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
2.20
|
2.14
|
2.63 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
3.32
|
2.27
|
1.21 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
Yes |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact
person |
No |
|
11] |
Turnover of firm for last
three years |
Yes |
|
12] |
Profitability for last
three years |
Yes |
|
13] |
Reasons for variation
<> 20% |
----- |
|
14] |
Estimation for coming
financial year |
No |
|
15] |
Capital in the business |
No |
|
16] |
Details of sister concerns |
No |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details
(if applicable) |
No |
|
21] |
Market information |
----- |
|
22] |
Litigations that the firm
/ promoter involved in |
----- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking
account |
---- |
|
26] |
Buyer visit details |
---- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if
applicable |
Yes |
|
29] |
Last accounts filed at
ROC |
Yes |
|
30] |
Major Shareholders, if
available |
Yes |
|
31] |
PAN of
Proprietor/Partner/Director, if available |
No |
|
32] |
Passport No of
Proprietor/Partner/Director, if available |
No |
|
33] |
Voter ID No of Proprietor/Partner/Director,
if available |
No |
OPERATIONS AND OVERALL PERFORMANCE
The operations of the Company for the year was
satisfactory. During the year sales has gone up as demand for our companies products
have been good.
FIXED ASSETS
·
Land
·
Building at Plot 1417
·
Building at Plot 1507
·
Building at Plot 1418
·
Building at Plot 1421
·
Building at Plot 1601
·
Building at Plot 1416
·
Building at Plot
1419/1420
·
Building at Plot 1601/03
and 04
·
Factory Sheld/ Building
·
Electrical Instalation
·
Plant and Machinery
·
Office Equipments
·
Furniture and Fixtures
·
Tools and Testing
Equipments
·
Motor Car
·
Boiler
·
Pipeline
·
Scooter
·
Testing Equipments
·
Heavy Equipments
·
Capital work in progress
– Building at plot 142
·
Capital work in progress
– Building at plot 150
·
Capital work in progress
– Pipe Line
·
Capital work in progress
– Plant and Machinery
·
Capital work in progress
– Furniture and Fixture
WEBSITE DETAILS
PROFILE
Subject is a leading manufacturer and
supplier of traditional and new generational API to the National and
International pharmaceutical community by offering stable and high quality
products, on continuous innovation and development. Founded in 1999, Vital was
set up with a modest installed capacity of 24 Tonnes p.a. for manufacturing
Quinine Salts and alkaloids.
Within a short span of 10 years it
has evolved itself into a plant covering area of 7980.55 sq. mtr. of land with
building of 86000 sq. feet and manufacturing 240 Tons p.a. with an impressive
clientele list of all, major Indian Pharmaceutical companies and exporters of
formulations. With exports being done to all continents, we have become a force
to reckon with.
Financial Strength, Reliable
indigenous technology flavoured with Constant innovation, a keen mind open to
new ideas and experiments coupled with Crystal Clear business practices and
self confidence brimming to the hilt are VITAL secrets of this stupendous
growth.
EXPORTS
Subject has created a name in the
manufacture and development of bulk actives surreptitiously. Its area of core
competence (API’s) backed by tireless efforts has made ‘Vital’ a preferred
supplier in global export arena. It is recognized as a “STAR EXPORT HOUSE”.
Efforts are afoot to increase the
market base in the large and remunerative European markets, for which ‘Vital’
has accelerated the ‘EUDMF’ filing programmes to build and nurture the new and
existing clientele. EUDMF for Quinine Sulphate and Quinine Hydrochloride have
already gained approvals by being awarded the Certificate of Suitability (COS)
by the European Directorate for the Quality of Medicines and Healthcare (EDQM)
‘Vital’ has seen exports grow over the last 3 years. Contribution of exports to
overall turnover is now almost 50%. By middle of 2010, we hope to have
accreditation of USFDA APPROVAL.
With these key factors in progress,
‘Vital’ shall see a substantial growth in exports in the years to come,
resulting into rise in contribution of exports significantly to overall
turnover.
Subject international coverage to
various countries by way of export includes United Kingdom, Germany, Korea,
Hong Kong, Bangladesh, Dubai, Syria, Turkey, Sudan, Kenya, Tanzania, Nigeria,
Uruguay, Congo, Columbia, USA, China, Mexico, Japan, Pakistan.
MANUFACTURING FACILITIES
Subject has two manufacturing facility
situated at GIDC- Vapi (Gujarat)-160 Kilometers from Mumbai-accessible both by
road and rail and is spread over a land area of 7701.86 sq meters and
15336 sq meter having built up area of 44000 sq feet. & 1, 10000 square
feet respectively
The Company has developed dedicated GMP
facility for accreditation of:
The facility has been inspected by EDQM for
CEP/COS of Quinine Sulphate (CEP 2005-117) and Quinine hydrochloride (CEP
2005-114) and has now been approved for cGMP Quality system ICH Q7
adopted by company and approved facility.
The main features for GMP facilities are:
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners, controlling
shareholders or senior officers as terrorist or terrorist organization or whom
notice had been received that all financial transactions involving their assets
have been blocked or convicted, found guilty or against whom a judgement or
order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper payments
to government officials for engaging in prohibited transactions or with
designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 55.15 |
|
|
1 |
Rs. 86.57 |
|
Euro |
1 |
Rs. 67.60 |
INFORMATION DETAILS
|
Information
Gathered by : |
-- |
|
|
|
|
Report Prepared
by : |
DPT |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
6 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
6 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
6 |
|
--CREDIT LINES |
1~10 |
5 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
YES |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
49 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.